Discovery of candidate antibodies and antigens for acute myeloid leukemia therapy by combining whole-cell phage display selection and CRISPR-Cas9 library screening
Koji Hashimoto, Verena Konetzki, Andoni Garitano-Trojaola, Sabrina Kraus, Sabrina R Friedel, Michael Hudecek, Haiyong Peng, Christoph Rader · 2026
Read Discovery of candidate antibodies and antigens for acute myeloid leukemia therapy by combining whole-cell phage display selection and CRISPR-Cas9 library screening by Koji Hashimoto, Verena Konetzki, Andoni Garitano-Trojaola, Sabrina Kraus, Sabrina R Friedel, Michael Hudecek, Haiyong Peng, Christoph Rader (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628138.txt.
Description
Finding targets on leukemia cells is the bottleneck for antibody therapy, and a 2026 study by Koji Hashimoto and co-authors pairs two hunting tools to break it. Acute myeloid leukemia still leans on harsh chemotherapy because its cells offer few safe handles for immune attack.
First, the team fished whole leukemia cells with a library of antibody fragments displayed on phages, and read the winners by sequencing. Twenty-eight antibodies bound the leukemia lines preferentially. A CRISPR knockout screen then revealed what three of them were gripping, by watching which gene loss made the binding vanish. Lead candidates were checked on real patient cells and in killer T cell assays. The pipeline offers a general route to new cancer targets.
Catalog record
| CREATOR | Koji Hashimoto, Verena Konetzki, Andoni Garitano-Trojaola, Sabrina Kraus, Sabrina R Friedel, Michael Hudecek, Haiyong Peng, Christoph Rader |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |